Acadia Pharmaceuticals Inc. specializes in the research, development, and commercialization of innovative therapeutics for central nervous system (CNS) disorders and rare diseases. The company's flagship product, NUPLAZID (pimavanserin), is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. Its second commercial product, DAYBUE (trofinetide), is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1, approved as the first treatment for Rett syndrome. Acadia's clinical pipeline includes mid- to late-stage programs targeting Alzheimer's disease psychosis, Prader-Willi syndrome, and other neuropsychiatric conditions. The company leverages strategic partnerships, such as its collaboration with Stoke Therapeutics for RNA-based medications, to expand its neurodevelopmental offerings.
